Compare Electronic Arts Inc. (EA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Electronic Arts Inc. vs Twist Bioscience Corp — how do they compare? Electronic Arts Inc. trades at $207.31 (market cap $51.97B), while Twist Bioscience Corp trades at $92.56 (market cap $5.76B). The key difference: Electronic Arts Inc. is far larger — about 9× Twist Bioscience Corp's market cap, and Electronic Arts Inc. pays a 0.37% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| EA | TWST | |
|---|---|---|
Market Cap | $51.97B | $5.76B |
Sector | Technology | Health |
52-Week High | $207.27 | $102.88 |
52-Week Low | $147.79 | $24.16 |
Enterprise Value | $50.54B | $5.69B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Electronic Arts (EA) trades at $206.65, showing modest daily gains of 0.15%. The stock exhibits a bullish technical structure with moving averages aligned positively, though oscillators signal caution with RSI levels above 70. Fundamentally, EA maintains strong profitability with 78.97% gross margins and 11.78% net income margins, but valuation metrics appear elevated with a P/E of 59.05 and P/S of 6.96. Recent business developments include the successful launch of EA SPORTS College Football 27 and the introduction of EA Advertising platform for in-game brand integration.
The outlook balances strong franchise execution against valuation concerns. Investment opportunities stem from EA's dominant gaming portfolio, recurring revenue streams, and new advertising monetization. Key risks include recent earnings misses, potential regulatory scrutiny of the rumored $55 billion Saudi acquisition (Reuters, June 24, 2026), and stretched valuation multiples that may limit near-term upside despite analyst consensus leaning positive.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
